Business
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai Henlius Biotech, Inc. (hereafter "Henlius"). The deal grants Henlius exclusive development and commercialization rights to HCB101 across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle Ea
About this update from Shanghai Henlius Biotech, Inc. Class H
[{"type":"text","content":"TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai Henlius Biotech, Inc. (hereafter "Henlius"). The deal grants Henlius exclusive development and commercialization rights to HCB101 across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle East and North Africa (MENA).","length":605,"tagName":"p"},{"type":"image","alt":"HanchorBio and Henlius Sign Licensing Deal for HCB101","displaySize":"","headline":null,"caption":"HanchorBio and Henlius Sign Licensing Deal for HCB101","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/730da035f0fda00c22e50b4b102a3077"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_gmull3PBv1cZMhIrgp.PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/730da035f0fda00c22e50b4b102a3077","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2722492/HanchorBio_and_Henlius_Sign_Licensing_Deal_for_HCB101.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the terms of the agreement, HanchorBio will receive an upfront payment of USD 10 million, with additional payments tied to development and regulatory milestones of up to USD 192 million. Henlius will also pay tiered royalties and assume full responsibility for development, manufacturing, and commercialization in the licensed territories. HanchorBio retains all rights outside the licensed regions.","length":410,"tagName":"p"},{"type":"image","alt":"HCB101 is a novel engineered SIRPα-IgG4 Fc fusion protein","displaySize":"","headline":null,"caption":"HCB101 is a novel engineered SIRPĪ±-IgG4 Fc fusion protein","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":300,"url":"https://media.zenfs.com/en/prnewswire.com/4b7022e70b896c6fd776b8a8693daebd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UpaprzvkxIw5v_ClEZqROA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUyOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4b7022e70b...